Did You Know? The Currently Marketed Vaxx for CV-19 Is Actually Still In Clinical Trials
Governments’ experimental CV-19 injection is an mRNA modification originally developed as an individualized skin cancer therapy. Estimated study completion date: May 15, 2023.
Politicians and unelected bureaucrats have zero authority to mandate the public participate in unsafe medical experiments.
This unnecessary and dangerous medical intervention has proven not to be safe or effective.
Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.
The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:
- As a 2-dose (separated by 21 days) schedule;
- At various different dose levels in Phase 1;
- As a booster;
- In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).
Link To_Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 43998 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Prevention |
| Official Title: | A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS |
| Actual Study Start Date : | April 29, 2020 |
| Estimated Primary Completion Date : | May 15, 2023 |
| Estimated Study Completion Date : | May 15, 2023 |
Link To_Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
According to VAERS (Vaccine Adverse Effects Reporting System), excluding “foreign reports” to VAERS 9,136 deaths were reported in the U.S. between Dec. 14, 2020, and Dec. 3, 2021 in America.
https://openvaers.com/
https://vaers.hhs.gov/
— Therefore, the vaccines have significant risks.
According to the WHO, there have been at least 2,457,386 adverse events world-wide. This is over 1,000,000 more cases than all adverse events reported over the last 53 years of all vaccines administered since 1968 combined (www.vigiaccess.org). Search Trade Name of Drug: COVID-19 Vaccine
— Therefore, the vaccines have significant risks.
The Unity Project | Do Not Comply: Nullify
#NotSafe #NotEffective